Dr. Kaiser Outlines the Latest Data on High-Risk Multiple Myeloma

By Blood Cancer Talks - Last Updated: October 18, 2023

In this episode of “Blood Cancer Talks,” the hosts are joined by Martin Kaiser, MD, of the Institute of Cancer Research and the Royal Marsden Hospital. Dr. Kaiser and the hosts discuss strategies to identify and treat patients with newly diagnosed high-risk multiple myeloma (MM).

They discuss key data from the phase II OPTIMUM trial, how to predict ultrahigh-risk myeloma by molecular profiling and how cytogenetic features shape risk.

The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM. Additionally, they discuss the outcomes of patients with a double-hit signature who were in the MASTER and GRIFFIN trials, as well as the impact of autologous hemopoietic stem cell transplant on decreasing measurable residual disease burden in high-risk MM.

This podcast originally appeared on Blood Cancer Talks.

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator

Angela Dispenzieri, MD, on Managing Newly Diagnosed AL Amyloidosis

ASH 2023 Myeloid Recap With Anand Patel, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Dr. Kaiser Outlines the Latest Data on High-Risk Multiple Myeloma

Related